Rezolute (RZLT) Competitors $7.83 +0.36 (+4.83%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RZLT vs. BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, TARS, IDYA, and OCULShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Rezolute vs. Its Competitors Bausch Health Cos Organon & Co. Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Rezolute (NASDAQ:RZLT) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Do institutionals and insiders believe in RZLT or BHC? 83.0% of Rezolute shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 20.0% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor RZLT or BHC? In the previous week, Rezolute had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Rezolute and 5 mentions for Bausch Health Cos. Rezolute's average media sentiment score of 0.80 beat Bausch Health Cos' score of 0.69 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RZLT or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Rezolute's net margin of 0.00%. Rezolute's return on equity of -70.09% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% Bausch Health Cos 0.99%-852.36%5.25% Which has higher earnings and valuation, RZLT or BHC? Bausch Health Cos has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-6.80Bausch Health Cos$9.86B0.25-$46M$0.2626.06 Do analysts rate RZLT or BHC? Rezolute currently has a consensus target price of $11.67, indicating a potential upside of 49.25%. Bausch Health Cos has a consensus target price of $9.00, indicating a potential upside of 32.84%. Given Rezolute's stronger consensus rating and higher probable upside, analysts plainly believe Rezolute is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, RZLT or BHC? Rezolute has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. SummaryRezolute and Bausch Health Cos tied by winning 8 of the 16 factors compared between the two stocks. Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezoluteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$678.57M$3.10B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-6.7821.3675.8126.51Price / SalesN/A386.19492.95166.26Price / CashN/A44.4425.8129.90Price / Book3.579.6112.836.31Net Income-$68.46M-$53.28M$3.28B$270.12M7 Day Performance-3.25%0.44%0.24%2.04%1 Month Performance20.26%4.68%4.59%6.25%1 Year Performance51.79%10.08%68.69%25.50% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute2.7412 of 5 stars$7.82+4.6%$11.67+49.2%+42.3%$678.57MN/A-6.7840Positive NewsUpcoming EarningsBHCBausch Health Cos4.5995 of 5 stars$7.33-0.3%$9.00+22.9%+13.4%$2.72B$9.63B28.1720,700Positive NewsOGNOrganon & Co.4.5075 of 5 stars$10.48+0.9%$17.33+65.5%-49.3%$2.70B$6.40B3.894,000Positive NewsKNSAKiniksa Pharmaceuticals International2.6799 of 5 stars$36.57+2.4%$41.17+12.6%+44.7%$2.65B$423.24M914.48220Positive NewsShort Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+25.2%$2.63BN/A-60.7630CGONCG Oncology2.4527 of 5 stars$33.69+1.9%$53.91+60.0%-0.6%$2.52B$1.14M-19.0361News CoverageAnalyst ForecastInsider TradeGap UpHigh Trading VolumeALVOAlvotech3.7298 of 5 stars$8.16-2.0%$14.00+71.6%-24.9%$2.51B$491.98M35.481,032Positive NewsShort Interest ↓CPRXCatalyst Pharmaceuticals4.9551 of 5 stars$20.08-1.0%$33.20+65.3%-2.3%$2.48B$491.73M12.1780Positive NewsAnalyst DowngradeTARSTarsus Pharmaceuticals2.5028 of 5 stars$56.89-1.3%$66.67+17.2%+49.1%$2.43B$182.95M-24.4250Positive NewsIDYAIDEAYA Biosciences3.971 of 5 stars$23.39-13.9%$45.77+95.7%-34.5%$2.38B$7M-6.1780High Trading VolumeOCULOcular Therapeutix3.8887 of 5 stars$12.71-6.5%$17.20+35.3%+39.3%$2.37B$63.72M-9.93230News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies BHC Alternatives OGN Alternatives KNSA Alternatives GMTX Alternatives CGON Alternatives ALVO Alternatives CPRX Alternatives TARS Alternatives IDYA Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RZLT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored(Please Ignore if Already Rich)Discover how to get access to a weekly livestream with TWO Pro Traders for a full month… And learn their un...Monument Traders Alliance | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RZLT Stock Alerts